Markets · 1 sources covering this

Celldex shares slip 15% as safety concerns cloud skin drug trial win

(Rewrites throughout to add company comments, adds shares in paragraph 2, analyst comment in paragraph 5)- Celldex Therapeutics said on Tuesday its experimental

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

Economic TimesLean R·1h ago
Celldex shares slip 15% as safety concerns cloud skin drug trial win
(Rewrites throughout to add company comments, adds shares in paragraph 2, analyst comment in paragraph 5)- Celldex Therapeutics said on Tuesday its experimental
Read at Economic Times →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/6e43dbf870e9af773a1ec42d4aabca6cd9151ad3"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Celldex shares slip 15% as safety concerns cloud skin drug trial win"></iframe>

Celldex shares slip 15% as safety concerns cloud skin drug trial win

How 1 sources are covering this

Celldex shares slip 15% as safety concerns cloud skin drug trial win

More from Markets

Why NSE IPO became India's 2nd-largest, not biggest: MD-CEO Ashishkumar Chauhan explains | Exclusive

Top breakout stocks to buy tomorrow: Swiggy, Welspun, Finolex, Vishal Mega Mart, Carborundum by Sumeet Bagadia | Targets

Hill-house backed Elevate Campuses raises Rs 945-crore anchor book

Runwal Enterprises sets IPO price band at Rs 290-305 per share

Reader

Trust & legal

Across the network